通过METTL3介导的m6A修改circRNF220调节miR-330-5p/幸存者轴以促进骨髓瘤进展
Feng Liu1, Wen Li1, Zhihui Jin1
1Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Journal of cancer research and clinical oncology
|October 14, 2023
概括
循环RNA RNF220 (circRNF220) 通过通过miR-330-5p/survivin轴向上调节幸存者来促进骨髓瘤的进展. 针对METTL3-调节的circRNF220为骨髓瘤提供了一个潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 循环RNAs (circRNAs) 是生理过程的关键调节者.
- circRNF220在骨髓瘤 (OS) 中的特定作用尚不清楚.
研究的目的:
- 为了阐明circRNF220在骨髓瘤 (OS) 进展中的调节机制.
- 研究circRNF220作为OS治疗点的潜力.
主要方法:
- 定量实时PCR (qRT-PCR) 用于基因表达分析.
- 甲基化RNA免疫沉降 (Me-RIP) 用于m6A评估.
- 细胞测试 (CCK-8,EdU,殖民地形成,Transwell,伤口愈合) 对于扩散和入侵.
- RNA免疫沉降 (RIP) 和 luciferase 记者测定用于结合相互作用.
- 异种移植模型用于体内验证.
主要成果:
- 在OS细胞和组织中,CircRNF220过度表达.
- 沉默circRNF220抑制OS细胞的增殖,入侵和运动 in vitro和瘤生长 in vivo.
- METTL3调节的circRNF220通过海绵化miR-330-5p调节生存,促进OS的进展.
结论:
- 通过miR-330-5p/生存途径,METTL3调节的circRNF220促进OS的进展.
- 准circRNF220为骨髓瘤管理提供了一个新的治疗途径.
相关概念视频
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K


